Therefore, RNA therapies hold promise for the treatment of NPC, and they can be used to target both the genetic causes (mutations in the NPC1 and NPC2 genes) as well as the epigenetic causes, such as the dysregulation of miRNAs. Here, NPC1 is linked to nasopharyngeal carcinoma.